Monday, March 24, 2025 12:17:35 AM
I never stated or suggested that DCVax-l was going to get MHRA approval for all cancer-based tumors (though I speculate that there is a change that NWBO could be going for a cancer-agnostic designation, which would explain the effort/size of the SAP and MHRA application and well as the current MHRA delay in approval).
I simply made a statement, in the context of a Merck buyout, that DCVax-L worked against all tumor-based cancers, which is consistent with DCVax-L's mechanism of action. If DCVax-L, tomorrow or in 2 years, became THE effective treatment of all tumor-based cancers, that would be even more of an incentive for Merck to buy NWBO.
But this is all speculation from a person who knows little about this matter. Best of luck, sincerely, to all real, honest, decent investors. To the fudders, ... fill in the blank.
I simply made a statement, in the context of a Merck buyout, that DCVax-L worked against all tumor-based cancers, which is consistent with DCVax-L's mechanism of action. If DCVax-L, tomorrow or in 2 years, became THE effective treatment of all tumor-based cancers, that would be even more of an incentive for Merck to buy NWBO.
But this is all speculation from a person who knows little about this matter. Best of luck, sincerely, to all real, honest, decent investors. To the fudders, ... fill in the blank.
"Against stupidity, we are defenseless"-- Dietrich Bonhoeffer, an anti-Nazi German Theologian, executed in the final days of the Nazi regime.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
